Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Ignacio MatosJuan Martin-LiberalAlonso Garcia-RuizCinta HierroMaria Ochoa de OlzaCristina ViaplanaAnalia AzaroMaria VieitoIrene BranaGemma MurJavier RosJose MateosGuillermo VillacampaRoger BerchéMafalda OliveiraMaria AlsinaElena ElezAna OakninEva Muñoz-CouseloJoan CarlesEnriqueta FelipJordi RodónJosep TaberneroRodrigo DienstmannRaquel Perez-LopezElena GarraldaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
HPD measured by TGR or by RECIST was observed in both cohorts of patients; however, in our series, there was an impact on survival only in the immune-checkpoint inhibitor cohort when evaluated by RECIST. We propose a new way to capture HPD using RECIST criteria that is intuitive and easy to use in daily clinical practice.